Perrigo Company plc (NYSE:PRGO) Given Consensus Rating of “Hold” by Analysts

Shares of Perrigo Company plc (NYSE:PRGO) have received a consensus rating of “Hold” from the six analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $19.3333.

PRGO has been the subject of several research reports. Weiss Ratings raised Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th.

Institutional Trading of Perrigo

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC increased its holdings in Perrigo by 1,495.6% during the 4th quarter. SG Americas Securities LLC now owns 134,433 shares of the company’s stock valued at $1,871,000 after acquiring an additional 126,008 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Perrigo by 7.9% in the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after purchasing an additional 1,101,154 shares in the last quarter. Sound Income Strategies LLC grew its position in shares of Perrigo by 58.6% in the fourth quarter. Sound Income Strategies LLC now owns 1,138,357 shares of the company’s stock valued at $17,110,000 after purchasing an additional 420,626 shares during the last quarter. BW Gestao de Investimentos Ltda. grew its position in shares of Perrigo by 7.7% in the third quarter. BW Gestao de Investimentos Ltda. now owns 1,582,119 shares of the company’s stock valued at $35,234,000 after purchasing an additional 112,595 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Perrigo by 2.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 7,695,238 shares of the company’s stock worth $171,367,000 after purchasing an additional 181,828 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Stock Performance

Shares of PRGO opened at $10.44 on Friday. Perrigo has a 1 year low of $9.23 and a 1 year high of $28.43. The stock has a market capitalization of $1.44 billion, a PE ratio of -0.80, a PEG ratio of 1.25 and a beta of 0.51. The company has a debt-to-equity ratio of 1.45, a quick ratio of 1.59 and a current ratio of 2.72. The stock has a 50-day simple moving average of $10.82 and a 200-day simple moving average of $12.05.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The business had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the business earned $0.60 EPS. The company’s revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, analysts predict that Perrigo will post 2.11 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were paid a dividend of $0.29 per share. The ex-dividend date was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a yield of 11.1%. Perrigo’s dividend payout ratio is currently -8.85%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.